Nom du produit:5-Bromo-6-chloronicotinic acid
IUPAC Name:5-bromo-6-chloropyridine-3-carboxylic acid
- CAS：29241-62-1
- Formule moléculaire：C6H3BrClNO2
- Pureté：95%
- Numéro de catalogue：CM102696
- Poids moléculaire：236.45
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:29241-62-1
- Formule moléculaire:C6H3BrClNO2
- Point de fusion:-
- Code SMILES:O=C(O)C1=CN=C(Cl)C(Br)=C1
- Densité:
- Numéro de catalogue:CM102696
- Poids moléculaire:236.45
- Point d'ébullition:370°C at 760 mmHg
- N° Mdl:MFCD01927098
- Stockage:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Asciminib
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.
Recherche 
+86 21 5895 0110 
